Prior notification of a concentration (Case M.10133 — Astorg/Nordic Capital/Novo/Bioclinica) (Text with EEA relevance) 2021/C 99/11
Date: 2021-03-23
Institutions: Directorate-General for Competition, European Commission
Subjects: data processing, economic concentration, health care, holding company, investment company, medical research, merger control, provision of services, software








C_2021099EN.01001901.xml










23.3.2021   


EN


Official Journal of the European Union


C 99/19






Prior notification of a concentration
(Case M.10133 — Astorg/Nordic Capital/Novo/Bioclinica)
(Text with EEA relevance)
(2021/C 99/11)

1.   
On 16 March 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).
This notification concerns the following undertakings:






—


Astorg Asset Management S.à r.l. (‘Astorg’, Luxembourg)










—


Nordic Capital IX Limited (‘Nordic Capital’, Jersey)










—


Novo Holdings A/S (‘Novo’, Denmark)










—


Bioclinica Holding I LP (‘Bioclinica’, USA)




Astorg, Nordic Capital and Novo acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of Bioclinica through eResearch Technology, Inc (‘ERT’, USA).
The concentration is accomplished by way of purchase of shares.


2.   
The business activities of the undertakings concerned are the following:






—


for Astorg: a global private equity firm,










—


for Nordic Capital: a private equity firm focused on healthcare, technology & payments, financial services, and industrial & business services,










—


for Novo: a holding company responsible for the management of the assets of the Novo Nordisk Foundation through investments in the life sciences and related areas and through minority investments of a financial and venture capital nature,










—


Astorg, Nordic Capital, and Novo jointly control ERT, a provider of software-enabled clinical research solutions,










—


for Bioclinica: a provider of software-enabled clinical research solutions, including medical imaging and cardiac safety services, clinical adjudication, randomization and trial supply management and optimization solutions, electronic and eSource data capture, clinical trial management software, and drug safety solutions.






3.   

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.



4.   
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.10133 — Astorg/Nordic Capital/Novo/Bioclinica
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu
Fax +32 22964301
Postal address:





European Commission




Directorate-General for Competition




Merger Registry




1049 Bruxelles/Brussel




BELGIQUE/BELGIË







(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).